Exploring Therapeutic Potential of Luteolin in Periodontal Therapy: A Scoping Review
-
Premalatha Bidadi Rajashekaraiah
,
Suman Basavaraju
,
Subbarao V. Madhunapantula
,
Chandan Shivamallu
,
Hemanth Kumar Somareddy
,
Veena Haranahalli Raghavan
Abstract
Periodontal disease is a destructive inflammatory process of the tooth-supporting tissues, that frequently results in tooth loss. Traditional periodontal therapies that use conventional instrumentation, often struggle to eliminate the disease effectively in inaccessible tooth parts. In addition, currently employed adjuvant agents in periodontal therapy have many undesirable side effects. This has encouraged the exploration of natural compounds with higher biocompatibility, therapeutic index, safety and lower cost. Luteolin, a flavonoid found in many herbs, vegetables, and fruits, exhibits several beneficial properties for periodontal health, suggesting that it could be an effective therapeutic agent in countering periodontal diseases. However, further exploration of its therapeutic potential is necessary. Thus, this study aimed to review the current evidence on luteolin’s therapeutic role in periodontal therapy. A comprehensive search in the scientific literature databases (PubMed, Scopus, and Web of Science) was conducted for studies investigating luteolin’s role in periodontal therapy. The search yielded 106 papers and after discarding 86 papers that did not fit the inclusion criteria, 20 studies were considered for analysis. These included 11 studies on cell lines, 4 related to animal experiments, 3 on microbiological profiling and 2 on human participants. Data regarding the study characteristics were extracted and summarized. All the evidence gathered from the reviewed papers consistently demonstrated that luteolin has potent biological activities such as anti-inflammatory, antioxidant and antimicrobial properties that combat the etiopathogenic factors affecting the establishment and progression of periodontal diseases. In conclusion, luteolin holds considerable promise as an adjuvant therapeutic agent in periodontal disease management. With further research, it could become a key component in periodontal treatment strategies.
Tonetti MS, Jepsen S, Jin L, Otomo-Corgel J. Impact of the global burden of periodontal diseases on health, nutrition and wellbeing of mankind: A call for global action. J Clin Periodontol 2017;44:456-462.
Machado V, Botelho J, Amaral A, Proença L, Alves R, et al. Prevalence and extent of chronic periodontitis and its risk factors in a Portuguese subpopulation: A retrospective cross-sectional study and analysis of clinical attachment loss. PeerJ 2018;6:e5258.
Woelber JP, Reichenbächer K, Groß T, Vach K, Ratka-Krüger P, et al. Dietary and nutraceutical interventions as an adjunct to non-surgical periodontal therapy—A systematic review. Nutrients 2023;15:1538.
Gasner NS, Schure RS. Periodontal Disease; StatPearls Publishing: Treasure Island, FL, USA, 2020. Available online: https://www.ncbi.nlm.nih.gov/books/NBK554590/
Nocini R, Lippi G, Mattiuzzi C. Periodontal disease: The portrait of an epidemic. J Public Health Emerg 2020;4:10.
Choi E, Jin J, Choi J, Choi I, Kim S. Effects of luteolin on the release of nitric oxide and Interleukin-6 by macrophages stimulated with lipopolysaccharide from Prevotella intermedia. J Periodontol 2011;82:1509-1517.
Zhang H, Ning R, Zhao Y, Yan Z, Chen Y. The mechanism of the Shuang Bai Su Qing recipe in treating periodontitis based on network pharmacology and molecular docking technology. Medicine 2023;102:44(e35139).
Kariu T, Hamada N, Lakshmyya K. Luteolin inhibits Porphyromonas gingivalis growth and alleviates alveolar bone destruction in experimental murine periodontitis. Biosci Biotechnol Biochem 2024;88:37-43.
Sharma MH, Deepika PC, Venkatesh MP, Chandan S, Shashikumar P. Efficacy of 3% Psidium guajava local drug delivery in the treatment of chronic periodontitis: A randomized controlled trial. J Int Oral Health 2021;13:17-23.
Luque-Bracho A, Rosales Y, Vergara-Buenaventura A. The benefits of propolis in periodontal therapy. A scoping review of preclinical and clinical studies. J Ethnopharmacol 2023;303:115926.
Arampatzis AS, Pampori A, Droutsa E, Laskari M, Karakostas P, et al. Occurrence of luteolin in the Greek flora, isolation of luteolin and its action for the treatment of periodontal diseases. Molecules 2023;28:7720.
Augusco MAC, Sarri DA, Panontin JF, Rodrigues MAM, Fernandes RdMN, et al. Extracts from the leaf of Couroupita guianensis (Aubl.): Phytochemical, toxicological analysis and evaluation of antioxidant and antimicrobial activities against oral microorganisms. Plants 2023;12:2327.
Singh A, Yadav S, Pathak P, Verma A, Yadav JP. Harnessing luteolin's therapeutic potential in human disorders: Medicinal significance, biological, clinical properties and analytical aspects. Pharmacol Res Mod Chin Med 2024;10:100401.
Muruganathan N, Dhanapal AR, Baskar V, Muthuramalingam P, Selvaraj D, et al. Recent updates on source, biosynthesis and therapeutic potential of natural flavonoid luteolin: A review. Metabolites 2022;12:1145.
Aziz N, Kim MY, Cho JY. Anti-inflammatory effects of luteolin: A review of in vitro, in vivo, and in silico studies. J Ethnopharmacol 2018;225:342-358.
Yang K, Song Y, Ge L, Su J, Wen Y, et al. Measurement and correlation of the solubilities of luteolin and rutin in five imidazole-based ionic liquids. Fluid Phase Equilib 2013;344:27-31.
Huang L, Kim M-Y, Cho JY. Immunopharmacological activities of luteolin in chronic diseases. Int J Mol Sci 2023;24:2136.
Liu L, Peng Z, Huang H, Xu Z, We X. Luteolin and apigenin activate the Oct-4/Sox2 signal via NFATc1 in human periodontal ligament cells. Cell Biol Int 2016;40:1094-1106.
Gutiérrez-Venegas G, Contreras-Sánchez A. Luteolin and fisetin inhibit the effects of lipopolysaccharide obtained from Porphyromonas gingivalis in human gingival fibroblasts. Mol Biol Rep 2013;40:477-485.
Quan H, Dai X, Liu M, Wu C, Wang D. Luteolin supports osteogenic differentiation of human periodontal ligament cells. BMC Oral Health 2019;19:229.
Casili G, Ardizzone A, Lanza M, Gugliandolo E, Portelli M, et al. Treatment with luteolin improves lipopolysaccharide induced periodontal diseases in rats. Biomedicines 2020;8:442.
Yuce BH, Toker H, Yildirim A, Tekin MB, Gevrek F, et al. The effect of luteolin in prevention of periodontal disease in Wistar rats. J Periodontol 2019;90:1481-1489.
Yamamoto H, Ogawa T. Antimicrobial activity of Perilla seed polyphenols against oral pathogenic bacteria. Biosci Biotechnol Biochem 2002;66:921-924.
Gutierrez-Venegas G, Gomez-Mora JA, Meraz-Rodríguez MA, Flores-Sanchez MA, Ortiz-Miranda LF. Effect of flavonoids on antimicrobial activity of microorganisms present in dental plaque. Heliyon 2019;5:e03013.
Yoshizawa S, Meguro M, Ohyama H, Takeuchi-Hatanaka K, Matsushita S, et al. Focal adhesion kinase mediates human leukocyte histocompatibility antigen class II-induced signaling in gingival fibroblasts. J Periodont Res 2007;42:572-579.
Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Goffmann TC, et al. The PRISMA 2020 statement: An updated guideline for reporting systematic reviews. BMJ 2021;372:n71.
Kostić M, Kitić D, Petrović MB, Jevtović-Stoimenov T, Jović M, et al. Anti-inflammatory effect of the Salvia sclarea L. ethanolic extract on lipopolysaccharide-induced periodontitis in rats. J Ethnopharmacol 2017;199:52-59.
Gutiérrez-Venegas G, Luna OA, Arreguín-Cano JA, Hernández-Bermúdez C. Myricetin blocks lipoteichoic acid-induced COX-2 expression in human gingival fibroblasts. Cell Mol Biol Lett 2014;19:126-139.
Gutiérrez-Venegas G, Kawasaki-Cárdenas P, Maldonado-Frías S. Luteolin inhibits lipopolysaccharide actions on human gingival fibroblasts. Eur J Pharmacol 2006;541:95-105.
Gutiérrez-Venegas G, Jiménez-Estrada M, Maldonado S. The effect of flavonoids on transduction mechanisms in lipopolysaccharide-treated human gingival fibroblasts. Int Immunopharmacol 2007;7:1199-1210.
Gutiérrez-Venegas G, Torras-Ceballos A, Gómez-Mora JA, Fernández-Rojas B. Luteolin, quercetin, genistein and quercetagetin inhibit the effects of lipopolysaccharide obtained from Porphyromonas gingivalis in H9c2 cardiomyoblasts. Cell Mol Biol Lett 2017;22:1-12.
Gutiérrez-Venegas G, Giroshi Bando-Campos C. The flavonoids luteolin and quercetagetin inhibit lipoteichoic acid actions on H9c2 cardiomyocytes. Int Immunopharmacol 2010;10:1003-1009.
Matsuta T, Sakagami H, Satoh K, Kanamoto T, Terakubo S, et al. Biological activity of luteolin glycosides and tricin from Sasa senanensis Rehder. In vivo 2011;25:757-762.
Alhassani AA, Hu FB, Rimm EB, Li Y, Rosner BA, et al. Dietary flavonoid intake and risk of periodontitis. J Periodontol 2020;91:1057-1066.
Sparrow TV, Dodington DW, Yumol JL, Fritz PC, Ward WE. Higher intakes of flavonoids are associated with lower salivary IL-1β and maintenance of periodontal health 3–4 years after scaling and root planing. J Clin Periodontol 2020;47:461-469.
Rakoczy K, Kaczor J, Sołtyk A, Szymańska N, Stecko J, et al. Application of luteolin in neoplasms and nonneoplastic diseases. Int J Mol Sci 2023;24:15995.
Jang CH, Moon N, Oh J, Kim JS. Luteolin shifts oxaliplatin-induced cell cycle arrest at G0/G1 to apoptosis in HCT116 human colorectal carcinoma cells. Nutrients 2019;11:770.
Palko-Labuz A, Sroda-Pomianek K, Uryga A, Kostrzewa-Suslow E, Michalak K. Anticancer activity of baicalein and luteolin studied in colorectal adenocarcinoma LoVo cells and in drug-resistant LoVo/Dx cells. Biomed Pharmacother 2017;88:232-241.
Hong J, Fristiohady A, Nguyen CH, Milovanovic D, Huttary N, et al. Apigenin and luteolin attenuate the breaching of MDA-MB231 breast cancer spheroids through the lymph endothelial barrier in vitro. Front Pharmacol 2018;9:317495.
Huang L, Jin K, Lan H. Luteolin inhibits cell cycle progression and induces apoptosis of breast cancer cells through downregulation of human telomerase reverse transcriptase. Oncol Lett 2019;17:3842-3850.
Tavsan Z, Kayali HA. Flavonoids showed anticancer effects on the ovarian cancer cells: Involvement of reactive oxygen species, apoptosis, cell cycle and invasion. Biomed Pharmacother 2019;116:109004.
Chen PY, Tien HJ, Chen SF, Horng CT, Tang HL, et al. Response of myeloid leukemia cells to luteolin is modulated by differentially expressed pituitary tumor-transforming gene 1 (PTTG1) oncoprotein. Int J Mol Sci 2018;19:1173.
Franco YE, de Lima CA, Rosa MN, Silva VA, Reis RM, et al. Investigation of U-251 cell death triggered by flavonoid luteolin: Towards a better understanding on its anticancer property against glioblastomas. Nat Prod Res 2021;35:4807-4813.
You Y, Wang R, Shao N, Zhi F, Yang Y. Luteolin suppresses tumor proliferation through inducing apoptosis and autophagy via MAPK activation in glioma. Onco Targets Ther 2019;23:83-96.
Ho HY, Chen PJ, Lo YS, Lin CC, Chuang YC, et al. Luteolin‐7‐O‐glucoside inhibits cell proliferation and modulates apoptosis through the AKT signaling pathway in human nasopharyngeal carcinoma. Environ Toxicol 2021;36:2013-2024.
Lee Y, Kwon YH. Regulation of apoptosis and autophagy by luteolin in human hepatocellular cancer Hep3B cells. Biochem Biophys Res Commun 2019;517:617-622.
Velmurugan BK, Lin JT, Mahalakshmi B, Chuang YC, Lin CC, et al. Luteolin-7-O-glucoside inhibits oral cancer cell migration and invasion by regulating matrix metalloproteinase-2 expression and extracellular signal-regulated kinase pathway. Biomolecules 2020;10:502.
Kou JJ, Shi JZ, He YY, Hao JJ, Zhang HY, et al. Luteolin alleviates cognitive impairment in Alzheimer’s disease mouse model via inhibiting endoplasmic reticulum stress-dependent neuroinflammation. Acta Pharmacol Sin 2022;43:840-849.
Qin L, Chen Z, Yang L, Shi H, Wu H, et al. Luteolin-7-O-glucoside protects dopaminergic neurons by activating estrogen-receptor-mediated signaling pathway in MPTP-induced mice. Toxicology 2019;426:152256.
Du Y, Liu P, Xu T, Pan D, Zhu H, et al. Luteolin modulates SERCA2a leading to attenuation of myocardial ischemia/reperfusion injury via sumoylation at lysine 585 in mice. Cell Physiol Biochem 2018;45:883-898.
Zhu S, Xu T, Luo Y, Zhang Y, Xuan H, et al. Luteolin enhances sarcoplasmic reticulum Ca2+-ATPase activity through p38 MAPK signaling thus improving rat cardiac function after ischemia/reperfusion. Cell Physiol Biochem 2017;41:999-1010.
Davella R, Mamidala E. Luteolin: A potential multiple targeted drug effectively inhibits diabetes mellitus protein targets. J Pharm Res Int 2021;33:161-171.
Lv J, Zhou D, Wang Y, Sun W, Zhang C, et al. Effects of luteolin on treatment of psoriasis by repressing HSP90. Int Immunopharmacol 2020;79:106070.
Palombo R, Savini I, Avigliano L, Madonna S, Cavani A, et al. Luteolin-7-glucoside inhibits IL-22/STAT3 pathway, reducing proliferation, acanthosis, and inflammation in keratinocytes and in mouse psoriatic model. Cell Death Dis 2016;7:e2344.
Góngora L, Giner RM, Máñez S, del Carmen Recio M, Ríos JL. Phagnalon rupestre as a source of compounds active on contact hypersensitivity. Planta Medica 2002;68:561-564.
Jo BG, Park NJ, Jegal J, Choi S, Lee SW, et al. Stellera chamaejasme and its main compound luteolin 7-O-glucoside alleviates skin lesions in oxazolone and 2, 4-dinitrochlorobenzene-stimulated murine models of atopic dermatitis. Planta Medica 2019;85:583-590.
Kwon EY, Kim SY, Choi MS. Luteolin-enriched artichoke leaf extract alleviates the metabolic syndrome in mice with high-fat diet-induced obesity. Nutrients 2018;10:979.
Park HS, Lee K, Kim SH, Hong MJ, Jeong NJ, et al. Luteolin improves hypercholesterolemia and glucose intolerance through LXRα‐dependent pathway in diet‐induced obese mice. J Food Biochem 2020;44:e13358.
Theoharides TC. COVID‐19, pulmonary mast cells, cytokine storms, and beneficial actions of luteolin. Biofactors 2020;46:306-308.
Dai LM, Cheng H, Li WP, Liu SQ, Chen MZ, et al. The influence of luteolin on experimental inflammatory models in rats. Acta Anhui Med Univ 1985;20:1-3.
B Fiszer-Szafaraz. The oral LD50 of luteolin in mice. Analyt Biochem 1984;143:76-84.
| Issue | Vol 10, No 2, 2025 (In Press) | |
| Section | Review Article(s) | |
| Keywords | ||
| Anti-inflammatory agents Antioxidants Luteolin Periodontal diseases | ||
| Rights and permissions | |
|
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
